Original Article

You have full text access to this OnlineOpen article

Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia

  1. Giovanni Almadori MD1,†,*,
  2. Francesco Bussu MD1,
  3. Pierluigi Navarra MD2,
  4. Jacopo Galli MD1,
  5. Gaetano Paludetti MD1,
  6. Bruno Giardina PhD3,
  7. Maurizio Maurizi MD1

Article first published online: 12 JUN 2006

DOI: 10.1002/cncr.22003

Issue

Cancer

Cancer

Volume 107, Issue 2, pages 328–336, 15 July 2006

Additional Information

How to Cite

Almadori, G., Bussu, F., Navarra, P., Galli, J., Paludetti, G., Giardina, B. and Maurizi, M. (2006), Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. Cancer, 107: 328–336. doi: 10.1002/cncr.22003

Author Information

  1. 1

    Institute of Otolaryngology, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy

  2. 2

    Institute of Pharmacology, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy

  3. 3

    Institute of Clinical Chemistry, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy

  1. †

    Fax: (011) 39 06 3051194

*Institute of Otolaryngology, Universita Cattolica del Sacro Cuore, Largo Gemelli 8, Rome 00168, Italy

Publication History

  1. Issue published online: 5 JUL 2006
  2. Article first published online: 12 JUN 2006
  3. Manuscript Accepted: 17 MAR 2006
  4. Manuscript Revised: 23 FEB 2006
  5. Manuscript Received: 21 NOV 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (225K)

Keywords:

  • folate;
  • head and neck cancer;
  • laryngeal cancer;
  • molecular epidemiology

The current results suggest the hypothesis that folate insufficiency is a long-term risk factor that increases the rate of carcinogenic progression after exposure to environmental carcinogens. The present pilot chemopreventive study seems encouraging, with a complete response rate of 27% and no clinical or histologic progression of leucoplakia after a 6-month treatment.

Abstract

BACKGROUND

It has been previously observed that patients with head and neck squamous cell carcinoma or with laryngeal leucoplakia present a significant reduction in plasma folate levels. The current Phase IIA pilot study assessed the effectiveness of folic acid as a chemopreventive agent in patients affected by glottic laryngeal leucoplakia,

METHODS

Forty-three untreated patients affected by glottic laryngeal leucoplakia were enrolled in the Ear, Nose, and Throat Department (Universita Cattolica del Saco Cuore, Rome, Italy). Glottic leucoplakia was initially diagnosed by indirect laryngoscopy and successively confirmed by diagnostic direct microlaryngoscopy with a biopsy for histologic assessment. Folic acid (Folina, Schwarz Pharma, Germany) was administered orally (5 mg every 8 hours) for 6 months. Patients were monitored every 30 days by videolaryngoscopy.

RESULTS

Twelve (28%) patients had no response, 19 (44%) had a partial response, and 12 (28%) had a complete response. The mean increase in serum folate levels (10.06 ± 0.53) and the mean decrease in homocysteine serum (3.65349 ± 0.85526) at the end of the study were highly significant (P = .0001).

CONCLUSIONS

The larynx is 1 of the sites of major interest and a good model for the development of chemopreventive agents, but so far the proposed agents have shown no clear efficacy on precancerous lesions or on the development of second malignancies. Cancer 2006. © 2006 American Cancer Society.

View Full Article (HTML) Get PDF (225K)